NASDAQ:LIAN LianBio (LIAN) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free LIAN Stock Alerts $0.28 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.28▼$0.2950-Day Range$0.28▼$4.9952-Week Range$0.27▼$4.99Volume186,926 shsAverage Volume1.04 million shsMarket Capitalization$30.58 millionP/E RatioN/ADividend YieldN/APrice Target$5.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get LianBio alerts: Email Address Ad American AlternativeUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...CLICK HERE TO GET YOUR GUIDE NOW About LianBio Stock (NASDAQ:LIAN)LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Read More LIAN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIAN Stock News HeadlinesMarch 15, 2024 | investorplace.comWhy Is LianBio (LIAN) Stock Moving Today?February 28, 2024 | globenewswire.comLianBio Announces Voluntarily Delisting from NasdaqApril 25, 2024 | American Alternative (Ad)Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...February 23, 2024 | seekingalpha.comWith No Cure In Sight, Drugs Firm LianBio Begins Exit StrategyFebruary 13, 2024 | markets.businessinsider.comLianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-MarketFebruary 13, 2024 | marketwatch.comLianBio to Wind Down Operations, Declares Special DividendFebruary 13, 2024 | marketwatch.comLianBio Shares Gain After Co Announces Plans to Wind DownFebruary 13, 2024 | finance.yahoo.comLianBio Announces Completion of Strategic ReviewApril 25, 2024 | American Alternative (Ad)Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...January 3, 2024 | markets.businessinsider.comB of A Securities Downgrades LianBio: Here's What You Need To KnowDecember 26, 2023 | markets.businessinsider.comNanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | finance.yahoo.comLianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsDecember 20, 2023 | realmoney.thestreet.comInterest Is Growing for Smaller, More Speculative NamesDecember 20, 2023 | finance.yahoo.comLianBio Announces Departure of Chief Financial OfficerDecember 19, 2023 | marketwatch.comLianBio Names Stone as Interim CEO as Wang ResignsDecember 19, 2023 | finance.yahoo.comLianBio Announces Departure of Chief Executive OfficerDecember 6, 2023 | finance.yahoo.comLianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra BiosciencesDecember 1, 2023 | finance.yahoo.comLianBio Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNovember 14, 2023 | finance.yahoo.comLianBio (LIAN) Reports Q3 2023 Financial Results: Strategic Review in Progress Amid Clinical ...November 13, 2023 | finance.yahoo.comLianBio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 8, 2023 | finance.yahoo.comAll You Need to Know About LianBio Sponsored ADR (LIAN) Rating Upgrade to Strong BuyOctober 30, 2023 | finance.yahoo.comLianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex BlepharitisOctober 27, 2023 | fool.comWhy LianBio Stock Is Shooting Through the Roof This WeekOctober 25, 2023 | finance.yahoo.comLianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023October 25, 2023 | markets.businessinsider.comRaymond James Maintains Outperform Rating for LianBio: Here's What You Need To KnowOctober 24, 2023 | markets.businessinsider.comLianBio Reaches Agreement With Bristol Myers Squibb For Mavacamten; Stock UpOctober 24, 2023 | marketwatch.comLianBio Shares Soar Premarket on Strategic Review, End of Bristol PactSee More Headlines Receive LIAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Dividend Payable3/14/2024Ex-Dividend for 3/14 Dividend3/15/2024Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:LIAN CUSIPN/A CIK1831283 Webwww.lianbio.com Phone609-486-2308FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Target$5.33 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,784.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E Ratio0.12 P/E GrowthN/ANet Income$-110,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.17% Return on Assets-30.19% Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book0.10Miscellaneous Outstanding Shares108,063,000Free Float99,861,000Market Cap$30.58 million OptionableNot Optionable Beta0.23 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Konstantin Poukalov (Age 40)Founder & Executive Chairman Mr. Adam Leo Stone (Age 43)Interim CEO & Director Ms. Ehong GuInterim CFO, VP & Head of Global FinanceJi ChenSenior VP & General CounselMs. Brianne Jahn (Age 38)Chief Business Officer Comp: $697.47kDr. Michael Humphries M.D.Chief Scientific AdvisorMr. Levvy Lv D. EngSenior VP & Global Head of DevelopmentMore ExecutivesKey CompetitorsTevogen BioNASDAQ:TVGNPHAXIAM TherapeuticsNASDAQ:PHXMAffimedNASDAQ:AFMDKinnate BiopharmaNASDAQ:KNTENGM BiopharmaceuticalsNASDAQ:NGMView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCBought 3,107,337 shares on 2/13/2024Ownership: 3.498%Axxcess Wealth Management LLCBought 10,536 shares on 2/6/2024Ownership: 0.025%View All Institutional Transactions LIAN Stock Analysis - Frequently Asked Questions Should I buy or sell LianBio stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LianBio in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LIAN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIAN, but not buy additional shares or sell existing shares. View LIAN analyst ratings or view top-rated stocks. What is LianBio's stock price target for 2024? 3 brokers have issued 1-year price targets for LianBio's stock. Their LIAN share price targets range from $3.00 to $9.00. On average, they expect the company's stock price to reach $5.33 in the next twelve months. This suggests a possible upside of 1,784.6% from the stock's current price. View analysts price targets for LIAN or view top-rated stocks among Wall Street analysts. How have LIAN shares performed in 2024? LianBio's stock was trading at $4.47 at the beginning of the year. Since then, LIAN stock has decreased by 93.7% and is now trading at $0.2830. View the best growth stocks for 2024 here. How were LianBio's earnings last quarter? LianBio (NASDAQ:LIAN) released its earnings results on Monday, March, 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.10. How often does LianBio pay dividends? What is the dividend yield for LianBio? LianBio declared a -- dividend on Tuesday, February 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $4.80 per share on Thursday, March 14th. The ex-dividend date is Friday, March 15th. Read our dividend analysis for LIAN. When did LianBio IPO? LianBio (LIAN) raised $325 million in an initial public offering on the week of November 1st 2021. The company issued 20,300,000 shares at a price of $16.00 per share. Goldman Sachs, Jefferies and BofA Securities acted as the underwriters for the IPO. How do I buy shares of LianBio? Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LIAN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
